Article Text

Download PDFPDF
Clinical Outcomes of Women With Recurrent or Persistent Uterine Leiomyosarcoma
  1. Jose Alejandro Rauh-Hain, MD*,
  2. Emily M. Hinchcliff, MD*,,
  3. Titilope Oduyebo, MD,
  4. Michael J. Worley, MD,
  5. Carolina A. Andrade*,
  6. John O. Schorge, MD*,
  7. Suzanne George, MD,
  8. Micheal G. Muto, MD and
  9. Marcela G. del Carmen, MD, MPH*
  1. *Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital,
  2. Division of Gynecologic Oncology, Brigham and Women’s Hospital, and
  3. Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  1. Address correspondence and reprint requests to Marcela G. del Carmen, MD, MPH, Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, 55 Fruit St, Yawkey 9 E, Boston, MA 02114. E-mail: mdelcarmen{at}partners.org.

Abstract

Objectives This study aimed to identify prognostic factors influencing the outcome of recurrent or persistent uterine leiomyosarcoma (ULMS).

Methods All patients with recurrent or persistent ULMS who underwent treatment at the participating institutions between January 2000 and December 2010 were identified from the tumor registry. The Kaplan-Meier method was used to generate overall survival data. Factors predictive of outcome were compared using the log-rank test and Cox proportional hazards model.

Results One hundred fifteen (68.8%) patients who had recurrent/persistent disease were identified, 40 (34.8%) had persistent disease, and 75 (65.2%) had a recurrence. Median follow-up time was 24.9 months. The 5-year postrelapse survival rate was 15% and was not significantly different between women with recurrent or persistent disease (16% vs 13%; P = 0.1). Variables identified affecting the 5-year postrelapse survival rate included low number of mitosis at the time of diagnosis (<25, 25% vs 5%; P = 0.002), time to relapse from original diagnosis (≤6 vs >6 months, 8% vs 22%; P = 0.003)), and surgical treatment (17% vs 12%; P = 0.01). Age, stage, chemotherapy at time of original diagnosis or at the time of relapse, site of recurrence, and single versus multiple sites of recurrence were not associated with survival. In a multivariate Cox regression model, only low number of mitosis (hazard ratio, 0.5; 95% confidence interval, 0.3–0.8, P = 0.02) was identified as a predictor of overall survival.

Conclusions The prognosis of patients with recurrent/persistent ULMS is, in general, poor. Women who have low number of mitosis at the time of diagnosis seemed to have better postrelapse survival.

  • Uterine leiomyosarcoma
  • Uterine cancer

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.